IMMUNOHISTOCHEMICAL DETECTION OF CA-125 AND CARCINOEMBRYONIC ANTIGEN IN OVARIAN-TUMORS IN RELATION TO CORRESPONDING PREOPERATIVE SERUM LEVELS

被引:10
作者
THOLANDER, B
LINDGREN, A
TAUBE, A
STENSON, S
机构
[1] UNIV HOSP UPPSALA,DEPT PATHOL,S-75185 UPPSALA,SWEDEN
[2] UNIV UPPSALA,DEPT STAT,S-75105 UPPSALA,SWEDEN
关键词
CA-125; CEA; IMMUNOCYTOCHEMISTRY; OVARIAN NEOPLASMS; SERODIAGNOSIS; TUMOR ANTIGENS;
D O I
10.1046/j.1525-1438.1992.02050263.x
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The immunohistochemically detectable expression of CA-125 and CEA in ovarian tumor tissue from 187 patients was related to corresponding preoperative serum levels. A strong positive association between tissue expression and the serum level of both the CA-125 and CEA antigens was found in cases of invasive epithelial ovarian carcinoma. However, this relationship was absent for CA-125 in borderline cases and patients with benign ovarian tumors, although the antigen frequently was detectable in them. The presence of ascites could be verified in 3 of 10 cases with benign CA-125 negative tumors, but elevated CA-125 levels in serum. 'False negative' CA-125 levels were found in 6 borderline and 7 true invasive carcinoma cases despite positive tissue staining. Eight of those patients had limited stage I disease. The data suggests that although the tissue expression of the CA-125 and CEA antigens in invasive ovarian carcinoma has an important influence in the corresponding serum level, compartment barriers and low cell turnover in benign, and to a lesser extent borderline, cases result in low serum levels. In addition, other factors influence serum levels of CA-125, such as secondary peritoneal response with or without ascites, which may cause 'falsely elevated' CA-125 results in benign disease.
引用
收藏
页码:263 / 270
页数:8
相关论文
共 37 条
[1]   A RADIOIMMUNOASSAY USING A MONOCLONAL-ANTIBODY TO MONITOR THE COURSE OF EPITHELIAL OVARIAN-CANCER [J].
BAST, RC ;
KLUG, TL ;
STJOHN, E ;
JENISON, E ;
NILOFF, JM ;
LAZARUS, H ;
BERKOWITZ, RS ;
LEAVITT, T ;
GRIFFITHS, CT ;
PARKER, L ;
ZURAWSKI, VR ;
KNAPP, RC .
NEW ENGLAND JOURNAL OF MEDICINE, 1983, 309 (15) :883-887
[2]   MONITORING HUMAN OVARIAN-CARCINOMA WITH A COMBINATION OF CA-125, CA-19-9, AND CARCINOEMBRYONIC ANTIGEN [J].
BAST, RC ;
KLUG, TL ;
SCHAETZL, E ;
LAVIN, P ;
NILOFF, JM ;
GREBER, TF ;
ZURAWSKI, VR ;
KNAPP, RC .
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY, 1984, 149 (05) :553-559
[3]   CA-125 (OVARIAN TUMOR-ASSOCIATED ANTIGEN) IN ASCITIC LIVER-DISEASES [J].
BERGMANN, JF ;
BEAUGRAND, M ;
LABADIE, H ;
BIDART, JM ;
BOHUON, C .
CLINICA CHIMICA ACTA, 1986, 155 (02) :163-165
[4]   COMPARISON BETWEEN TISSUE AND SERUM CONTENT OF CA-125, CA-19-9, AND CARCINOEMBRYONIC ANTIGEN IN OVARIAN-TUMORS [J].
BREITENECKER, G ;
NEUNTEUFEL, W ;
BIEGLMAYER, C ;
KOLBL, H ;
SCHIEDER, K .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1989, 8 (02) :97-102
[5]  
BUSCH C, 1988, ANTICANCER RES, V8, P81
[6]   CARCINOEMBRYONIC ANTIGEN (CEA) AND CARBOHYDRATE DETERMINANT 19-9 (CA 19-9) LOCALIZATION IN 121 PRIMARY AND METASTATIC OVARIAN-TUMORS - AN IMMUNOHISTOCHEMICAL STUDY WITH THE USE OF MONOCLONAL-ANTIBODIES [J].
CHARPIN, C ;
BHAN, AK ;
ZURAWSKI, VR ;
SCULLY, RE .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1982, 1 (03) :231-245
[7]  
CURRAN RC, 1977, EXPERIENTIA, V33, P1400, DOI 10.1007/BF01920206
[8]  
EINHORN N, 1986, OBSTET GYNECOL, V67, P414
[9]  
FALINI B, 1983, ARCH PATHOL LAB MED, V107, P105
[10]  
FLEUREN GJ, 1987, CANCER, V60, P2437, DOI 10.1002/1097-0142(19871115)60:10<2437::AID-CNCR2820601015>3.0.CO